ESR1 and breast carcinoma: The lincRNA termed lncRNA in non-homologous end joining (NHEJ) pathway 1 (LINP1), which was first determined to be overexpressed in triple-negative breast cancer, improves tamoxifen resistance in ER+ breast cancer [198].